Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Executive Summary
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
You may also be interested in...
CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Deal Watch: Deal Volume On The Rise Heading Into J.P. Morgan
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
J.P. Morgan 2021: The Show Must Go On
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.
Need a specific report? 1000+ reports available
Buy Reports